Rezolute, Largely Owned by Handok and Genexine, Announces Major Result of U.S. Clinical Trial Phase Ib for Oral Diab..

On February 22, 2022 (local time), Rezolute, Inc., a U.S. bio-venture in which Handok and Genexine are the largest shareholders, announced a major positive outcome during the U.S. Phase Ib multiple-dose escalation (MAD) study for RZ402. This outcome reconfirms that RZ402 may be orally administered once daily. Rezolute ..

Handok Signs Domestic Joint Promotion and Sales Agreement with Sanofi-Aventis Korea for Treatment of Hyperphospha..

On February 10, 2022, Handok signed a domestic joint promotion and sales agreement with Sanofi-Aventis Korea (Bae Kyung-eun, CEO) for Renvela, a treatment for hyperphosphatemia, at Handok headquarters in Yeoksam-dong, Seoul. Handok has been strengthening its competitiveness in the treatment of the human kidney. It h..

Handok wins U.S. FDA Approval for Phase II Clinal Trial for Next-Generation Anticancer Treatment ABL001 (CTX-00..

Compass Therapeutics, a U.S. company in collaboration with Handok, received approval on January 18, 2022 (local time) for its Phase II clinical trial plans (Investigational New Drug Application: IND) for ABL001 (CTX-009), a next-generation anticancer treatment, from the U.S. Food and Drug Administration. This approv..